Bristol Myers Squibb Unveils $2.3 Billion Manufacturing Campus in Houston

Bristol Myers Squibb (NYSE:BMY) has announced the establishment of a new, state-of-the-art manufacturing campus in Houston, Texas, with an investment of approximately $2.3 billion. This facility, located at Generation Park, is set to create nearly 500 skilled jobs and is designed for long-term growth and adaptability, supporting the delivery of next-generation medicines.

The Houston campus represents a significant step in BMS's ongoing commitment to invest $40 billion in the United States over five years, focusing on research and development, technology, and domestic manufacturing. The modular and multi-modal design of the campus will allow for flexible manufacturing of various types of medicines, including small molecules, biologics, and antibody-drug conjugates, across multiple disease areas. This adaptability ensures the facility can evolve to meet the needs of patients well into the future.

Christopher Boerner, Ph.D., Board Chair and CEO of Bristol Myers Squibb, expressed confidence in the investment: "This investment reflects our confidence in America's continued leadership in biopharmaceutical innovation. As part of our $40 billion commitment to the United States, we're building the domestic manufacturing capabilities needed to deliver the next generation of medicines and support future scientific breakthroughs. Houston and the state of Texas offer the talent, infrastructure, and partnership needed to help bring that vision to life."

Texas Governor Greg Abbott praised the initiative, stating, “Texas is a global hub for life sciences, where today’s innovations shape the future of healthcare. This $2.3 billion investment by Bristol Myers Squibb in the dynamic biotech ecosystem in Houston is a testament to the depth of our skilled workforce and the pipeline of talent coming through our nation-leading technical colleges and research universities. With lower operating costs and easy access to markets across the U.S. and the world, Texas drives affordability for consumers.”

U.S. Secretary of Commerce Howard Lutnick emphasized the broader economic implications: "We are making pharmaceuticals in America again thanks to President Trump’s America First Trade Agenda. Bristol Myers Squibb’s $2.3 billion investment in Texas will create hundreds of high-paying jobs and strengthen our pharmaceutical supply chains, ensuring America is never reliant on foreign sources for critical medicines."

Karin Shanahan, EVP and Chief Supply Chain and Operations Officer of Bristol Myers Squibb, noted the strategic importance of the facility: "Our decision to build this state-of-the-art manufacturing campus in Houston, Texas, reflects our confidence in the region’s ability to support a world-class, digitally advanced supply operation. This facility is designed to deliver the speed, quality, and reliability that patients depend on, combining flexible, modular manufacturing with advanced digital capabilities to ensure consistent supply across multiple modalities."

The Houston campus will span approximately 600,000 square feet, designed for flexibility and long-term growth. It is strategically located in Generation Park, a 4,300-acre hub for life sciences and advanced manufacturing, also home to other major players in the industry. The construction is expected to create around 2,000 additional jobs, supporting the local economy.

BMS's investment not only enhances its domestic manufacturing capabilities but also reinforces the resilience of the U.S. pharmaceutical supply chain. With the biopharmaceutical industry employing over one million workers in 2022, this new campus is set to contribute significantly to the local and national economy.

BMS's commitment to Texas is evident as the company continues to collaborate with local contract manufacturers and has established numerous clinical trial sites throughout the state. This investment reflects a long-term vision for the workforce, communities, and patients who will benefit from the medicines produced in this new facility.

About Bristol Myers Squibb: Transforming Patients’ Lives Through Science
At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what’s possible for the future of medicine and the patients we serve. For more information, visit us at BMS.com and follow us on LinkedIn, X, YouTube, Facebook, and Instagram.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, the research, development, manufacturing, and commercialization of pharmaceutical products. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Such forward-looking statements are based on current expectations and projections about our future financial results, goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond our control and could cause our future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. These risks, assumptions, uncertainties and other factors include, among others, any delay or inability of Bristol Myers Squibb to realize the expected benefits of the proposed investment described in this press release. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Bristol Myers Squibb’s business and market, particularly those identified in the cautionary statement and risk factors discussion in Bristol Myers Squibb’s Annual Report on Form 10-K for the year ended December 31, 2025, as updated by our subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the Securities and Exchange Commission. The forward-looking statements included in this document are made only as of the date of this document and except as otherwise required by applicable law, Bristol Myers Squibb undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise.